UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baseline

HIV medicine, 2012-08, Vol.13 (7), p.398-405

2012

Volltextzugriff (PDF)

Impact of baseline HIV‐1 RNA levels on initial highly active antiretroviral therapy outcome: a meta‐analysis of 12,370 patients in 21 clinical trials

HIV medicine, 2013-05, Vol.14 (5), p.284-292

2013

Volltextzugriff (PDF)

Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two‐panel, two‐way, two‐period, randomized trial

HIV medicine, 2013-08, Vol.14 (7), p.421-429

2013

Volltextzugriff (PDF)

PdCu membrane applied to hydrogen production from methane

Journal of membrane science, 2012-10, Vol.415-416, p.66-74

2012

Volltextzugriff (PDF)

Copper deposition on Pd membranes by electroless plating

International journal of hydrogen energy, 2011-10, Vol.36 (20), p.13114-13121

2011

Volltextzugriff (PDF)

Dewatering of organics by pervaporation with silica membranes

Separation and purification technology, 2001-03, Vol.22 (1-3), p.361-366

2001

Volltextzugriff (PDF)

On the potential of nickel catalysts for steam reforming in membrane reactors

Catalysis today, 2010-10, Vol.156 (3), p.153-164

2010

Volltextzugriff (PDF)

PdCu membrane integration and lifetime in the production of hydrogen from methane

International journal of hydrogen energy, 2013-06, Vol.38 (18), p.7659-7666

2013

Volltextzugriff (PDF)

Predictors of long‐term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial

Journal of the International AIDS Society, 2012-11, Vol.15 (S4), p.1-1

2012

Volltextzugriff (PDF)

Effects of switching to PI monotherapy on measures of lipoatrophy: meta‐analysis of six randomized HIV clinical trials

Journal of the International AIDS Society, 2012-11, Vol.15 (S4), p.1-1

2012

Volltextzugriff (PDF)

Thin PdCu membrane for hydrogen purification from in-situ produced methane reforming complex mixtures containing H2S

Chemical engineering science, 2018-02, Vol.176, p.429-438

2018

Volltextzugriff (PDF)

Hydrogen permeation through palladium membranes and inhibition by carbon monoxide, carbon dioxide, and steam

Journal of membrane science, 2015-12, Vol.496, p.344-358

2015

Volltextzugriff (PDF)

The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment‐naïve patients

Journal of the International AIDS Society, 2010-11, Vol.13 (S4), p.O47-O47

2010

Volltextzugriff (PDF)

Analysis of major and minor IAS‐USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs

Journal of the International AIDS Society, 2010-11, Vol.13 (S4), p.P131-P131

2010

Volltextzugriff (PDF)

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

International journal of STD & AIDS, 2010-03, Vol.21 (3), p.224-225

2010

Volltextzugriff (PDF)

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

AIDS (London), 2010-01, Vol.24 (2), p.223-230

2010

Volltextzugriff (PDF)

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline

Journal of antimicrobial chemotherapy, 2011-08, Vol.66 (8), p.1878-1885

2011

Volltextzugriff (PDF)

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results

AIDS (London), 2011-11, Vol.25 (18), p.2249-2258

2011

Volltextzugriff (PDF)

Solid Oxide Cell Technology Development at TNO

ECS transactions, 2021, Vol.103 (1), p.591-602

2021

Volltextzugriff (PDF)

No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial

PloS one, 2014, Vol.9 (11), p.e109718

2014

Volltextzugriff (PDF)

Low‐level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial

Journal of the International AIDS Society, 2010-11, Vol.13 (S4), p.O19-O19

2010

Volltextzugriff (PDF)

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

AIDS (London), 2011-01, Vol.25 (3), p.335-340

2011

Volltextzugriff (PDF)

Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial

Journal of antimicrobial chemotherapy, 2012-07, Vol.67 (7), p.1804-1806

2012

Volltextzugriff (PDF)

Performance of the Abbott RealTime HIV-1 assay versus the Roche Amplicor HIV-1 MonitorTM Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers

Journal of antimicrobial chemotherapy, 2014-06, Vol.69 (6), p.1708-1710

2014

Volltextzugriff (PDF)

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

The lancet HIV, 2019-09, Vol.6 (9), p.e588-e600

2019

Volltextzugriff (PDF)

1 – 25 von 247

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(185)
Mit Volltextzugriff
(187)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

Englisch
(145)
Französisch
(100)
Deutsch
(3)

Erscheinungsjahr

n.n

Thema

Science & Technology
(100)
Life Sciences & Biomedicine
(54)
Humans
(36)
Physical Sciences
(36)
Technology
(29)
Physics
(27)
Male
(23)
Female
(20)
Infectious Diseases
(19)
Materials Science
(18)
Biological And Medical Sciences
(17)
Hiv Infections - Drug Therapy
(14)
Medical Sciences
(14)
Adult
(13)
Chemistry
(13)
Materials Science, Multidisciplinary
(13)
Animals
(12)
Exact Sciences And Technology
(12)
Darunavir
(11)
Engineering
(11)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

The MONET trial: week 144 analysis of the efficacy of darunavir/ritonavir (DRV/r) monotherapy versus DRV/r plus two nucleoside reverse transcriptase inhibitors, for patients with viral load < 50 HIV‐1 RNA copies/mL at baseline

Impact of baseline HIV‐1 RNA levels on initial highly active antiretroviral therapy outcome: a meta‐analysis of 12,370 patients in 21 clinical trials

Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two‐panel, two‐way, two‐period, randomized trial

PdCu membrane applied to hydrogen production from methane

Copper deposition on Pd membranes by electroless plating

Dewatering of organics by pervaporation with silica membranes

On the potential of nickel catalysts for steam reforming in membrane reactors

PdCu membrane integration and lifetime in the production of hydrogen from methane

Predictors of long‐term HIV RNA suppression on darunavir/ritonavir monotherapy in the MONET trial

Effects of switching to PI monotherapy on measures of lipoatrophy: meta‐analysis of six randomized HIV clinical trials

Thin PdCu membrane for hydrogen purification from in-situ produced methane reforming complex mixtures containing H2S

Hydrogen permeation through palladium membranes and inhibition by carbon monoxide, carbon dioxide, and steam

The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment‐naïve patients

Analysis of major and minor IAS‐USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs

HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme

The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml

96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA <50 copies/mL at baseline

Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients: 48-week results

Solid Oxide Cell Technology Development at TNO

No difference in the rate of change in telomere length or telomerase activity in HIV-infected patients after three years of darunavir/ritonavir with and without nucleoside analogues in the MONET trial

Low‐level viraemia during treatment with darunavir/r monotherapy versus DRV/r + 2NRTIs in the MONET trial

A comparison of neuropsychiatric adverse events during 12 weeks of treatment with etravirine and efavirenz in a treatment-naive, HIV-1-infected population

Interleukin-6 and C-reactive protein levels after 3 years of treatment with darunavir/ritonavir monotherapy or darunavir/ritonavir + two nucleoside reverse transcriptase inhibitors in the MONET trial

Performance of the Abbott RealTime HIV-1 assay versus the Roche Amplicor HIV-1 MonitorTM Test, v1.5, UltraSensitive assay for samples with low plasma HIV-1 RNA copy numbers

Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy study

Suchergebnisse filtern